Assessment of Safety of Olaparib in Chinese Patients With Ovarian Cancer in the Real-World Setting
CompletedOBSERVATIONAL
Enrollment
2,506
Participants
Timeline
Start Date
April 29, 2024
Primary Completion Date
July 15, 2024
Study Completion Date
July 15, 2024
Conditions
Using NCID Database to Assess the Safety of Olaparib in Chinese Patients With Ovarian Cancer by Examining the Incidence, Seriousness, and Severity of All AE
Trial Locations (1)
100021
Chinese Academy of Medical Sciences Cancer Hospital, Beijing